Press "Enter" to skip to content

Federal Watchdog Finds No One Is Overseeing the Medical Office That Treats Congress and the Supreme Court

The physicians and pharmacists who care for members of Congress and Supreme Court justices operate largely outside the reach of federal oversight — and a new government report says that gap in accountability puts both patients and medical staff at risk. A Defense Department watchdog has now laid out exactly how that happened, and what needs to change.

The Defense Department Inspector General released findings Friday from an investigation into the Office of the Attending Physician, the Navy-staffed medical office that provides healthcare and prescription drugs to U.S. lawmakers and members of the nation’s highest court. The report was published amid allegations of misconduct and reports that Attending Physician Rear Adm. Brian Monahan had resigned earlier in the week.

As of August 2025, the OAP employed five physicians, two pharmacists, and 11 corpsmen. Despite serving some of the most powerful figures in the United States government, the office has gone largely unchecked by any federal authority — a situation the IG says has been building for more than a decade.

How the Oversight Gap Developed

The roots of the problem trace back to 2013, when oversight of Walter Reed National Military Medical Center shifted from the Navy to the Defense Health Agency. That transition came without any written guidance on how the DHA should handle supervision of the OAP — an office that, critically, is not classified as a Military Treatment Facility.

The report explained the resulting confusion directly:

“The gap in oversight is, in part, because the DHA has responsibility for overseeing [military treatment facilities], but the OAP is not [a Military Treatment Facility].”

Before 2013, Walter Reed personnel had been credentialing OAP medical staff since 1994. When authority transferred to the DHA, no one formally took responsibility for clinical quality management of the Navy personnel staffing the congressional medical office. The IG found that today, no branch of the Defense Department believes it holds that authority.

Attempts to fill the void have repeatedly fallen short. Walter Reed’s efforts to send pharmacy staff on assistance visits were turned away. The DHA’s requests to access internal OAP records were denied. The office has effectively shielded itself from the military medical oversight structure it technically sits within.

The report summed up the stakes plainly:

“The absence of [DoD] oversight of clinical quality management and pharmacy operations increases the risks to both patients and Navy medical personnel assigned to the OAP. Without the [DoD] conducting its mandated clinical quality management oversight of Navy medical personnel assigned to the OAP, the [DoD] cannot monitor provider readiness skills, professional competencies, and compliance with Federal law.”

Pharmacy Concerns and Medication Discrepancies

Among the most pointed findings in the report involves the OAP’s pharmacy operations. Federal law requires that controlled substances be regularly inspected, but the IG found no evidence that either the Drug Enforcement Agency or the Defense Department had ever visited the OAP pharmacy to conduct a review.

The OAP did invite the Walter Reed Controlled Substance Inventory Board to observe its pharmaceutical inventory seven times between January 2023 and February 2026 — but that fell short of the number mandated by both the Navy and the DHA. And while that board can count drugs and review records, it has no authority to implement corrective action.

During those visits, the board identified five medication inconsistencies, including missing prescription records in the medical bags used to transport drugs during congressional travel. The IG was unable to confirm whether any of those five problems had been corrected.

Personnel familiar with the office’s daily operations described a culture of selective compliance. The report noted that

“Navy medical personnel with direct knowledge of OAP operations stated that OAP personnel only ‘loosely’ follow naval pharmacy guidelines and that the OAP is not required to, and does not, allow [DoD] pharmacy inspections.”

A Difficult Investigation

Reaching these conclusions was not straightforward. The IG encountered significant resistance throughout the investigation, beginning with Monahan himself, who declined to participate and directed the watchdog to congressional counsel for any further communication.

When the IG sought to work around that obstacle — asking Monahan on March 9, 2026, to connect investigators with another OAP contact — the U.S. House of Representatives deputy general counsel responded the following day, informing the DoD IG that Navy personnel assigned to the OAP could not speak with investigators without congressional approval.

The IG chose not to challenge that position and pivoted to interviewing personnel from the Navy, Defense Health Agency, and Defense Department. A final attempt to access OAP records and interview staff was made on August 13, 2026, but was again denied by the House deputy general counsel.

The Naval Inspector General had previously faced the same barrier when seeking information from the OAP. As a result of these combined roadblocks, the DoD IG never gained access to a wide range of internal materials, including clinical quality management policies, internal pharmacy procedures, prescription records, climate assessments, or internal peer reviews.

The IG’s investigation drew on interviews with former and current Defense Department personnel who had worked in the OAP, as well as a review of DoD Hotline complaints filed between August 2023 and January 2026.

What the IG Recommends

The Inspector General put forward several recommendations aimed at closing the oversight gap. The Defense Department should designate an administrative body with clear authority over OAP medical personnel and establish formal policies for that body to follow. If that proves unworkable, the DoD should coordinate directly with the House and Senate to ensure adequate care standards are met.

The IG also recommended that pharmacy inspection records at the OAP be formally reviewed, and that the DoD or DEA conduct additional inspections of the OAP pharmacy if any violations of federal law are uncovered.